Serum bactericidal antibody titres against serogroup C meningococci in Turkish children: serological basis of the need for conjugated meningococcal vaccine
Abstract number: 1733_583
Yildirim I., Ceyhan M., Balmer P., Andrews N., Borrow R., Aydogan A., Ecevit C., Turgut M., Kurt N., Uysal G.
Like many other developing countries; there is no accurate information about the distribution of Neisseria meningitidis serogroups and the potential need for a conjugated meningococcal C vaccination programme in Turkey. To evaluate the need for this vaccine in our country we collected serum samples from four health centres located in different geographic regions and stratified according to age. Sera were tested for serum bactericidal antibodies (SBA) to serogroup C meningococci using rabbit serum as the complement source. It was observed that 98 (29.8%) and 40 (12.2%) of 329 individuals within the study population achieved SBA titer of >8 and >128, respectively. Overall; at least 70.2% of the population are susceptible (SBA titer <8) to meningoccal serogroup C disease. The rate of susceptibility was highest in infants aged 712 months and young children (14 years). Although the true incidence of meningococcal serogroup C disease is not well-known in Turkey, conjugated meningococcal C vaccine should be in mind as candidate vaccine for routine immunisation schedule given the high rate of susceptibility of the Turkish population.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|